Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine &bgr;-3 adrenergic receptor agonists

US6506901B2 · kind B2 · utility

Assignee

• Wyeth, LLC · US

Inventors

• Robert J. Steffan · Langhorne, US
• Mark Anthony Ashwell · Plainsboro, US
• Jeffrey Claude Pelletier · Whitemarsh, US
• William Ronald Solvibile · Monmouth Junction, US
• Edward Matelan · Royersford, US

Key dates

• Filing date: Jul 12, 2001
• Grant date: Jan 14, 2003
• Expiry date: Jul 12, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention provides compounds of Formula I having the structure wherein A, B, Z, R and R1 are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.